Skip to main content
Erschienen in: Strahlentherapie und Onkologie 10/2013

01.10.2013 | Original article

Impact of the HPV-positivity definition on the prognostic value of HPV status in patients with locally advanced squamous cell carcinoma of the head and neck

verfasst von: D. Rades, M.D., N.D. Seibold, M.P. Gebhard, F. Noack, M.D., C. Thorns, M.D., S.E. Schild, M.D.

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

This study re-evaluated the prognostic value of HPV status for loco-regional control (LRC), metastases-free survival (MFS), and survival (OS) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). A modified definition of HPV positivity was used in the current study compared to the authors’ previous study.

Patients and methods

In the previous study of the same 170 patients, a tumor was defined as HPV-positive if it showed a positive in situ hybridization result in ≥ 10 % of tumor cells and/or positive p16 immunostaining. In the current analysis, tumors were considered HPV-positive only if they showed positive results for both in situ hybridization and p16 immunostaining. In addition to HPV status, the same 11 potential prognostic factors were investigated for treatment outcomes as in the preceding study.

Results

In the multivariate analysis of the current study, HPV positivity was significantly associated with improved LRC [risk ratio (RR) 9.78; p < 0.001], MFS (RR 7.17; p = 0.008), and OS (RR 6.61; p < 0.001). In the previous study, HPV positivity was associated with LRC (RR 2.34; p = 0.014) and OS (RR 2.19; p = 0.019), but not with MFS (RR 2.04; p = 0.11).

Conclusions

Applying the new definition of HPV positivity, the impact of HPV status on the prognosis of patients irradiated for locally advanced SCCHN was more prominent than in our previous study and associated with all three investigated endpoints.
Literatur
1.
Zurück zum Zitat Cerezo L, Millan I, Torre A et al (1992) Prognostic factors for survival and tumor control in cervical lymph node metastases from head and neck cancer. A multivariate study of 492 cases. Cancer 69:1224–1234PubMedCrossRef Cerezo L, Millan I, Torre A et al (1992) Prognostic factors for survival and tumor control in cervical lymph node metastases from head and neck cancer. A multivariate study of 492 cases. Cancer 69:1224–1234PubMedCrossRef
2.
Zurück zum Zitat Cvek J, Kubes J, Skacelikova E et al (2012) Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70–75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study. Strahlenther Onkol 188:666–670PubMedCrossRef Cvek J, Kubes J, Skacelikova E et al (2012) Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70–75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study. Strahlenther Onkol 188:666–670PubMedCrossRef
3.
Zurück zum Zitat Denis F, Garaud P, Bardet E et al (2004) Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22:69–76PubMedCrossRef Denis F, Garaud P, Bardet E et al (2004) Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22:69–76PubMedCrossRef
4.
Zurück zum Zitat Fakhry C, Westra WH, Li S et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261–269PubMedCrossRef Fakhry C, Westra WH, Li S et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261–269PubMedCrossRef
5.
Zurück zum Zitat Hong AM, Dobbins TA, Lee CS et al (2010) Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer 103:1510–1517PubMedCrossRef Hong AM, Dobbins TA, Lee CS et al (2010) Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer 103:1510–1517PubMedCrossRef
6.
Zurück zum Zitat Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef
7.
Zurück zum Zitat Lee WR, Berkey B, Marcial V et al (1998) Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 42:1069–1075PubMedCrossRef Lee WR, Berkey B, Marcial V et al (1998) Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 42:1069–1075PubMedCrossRef
8.
Zurück zum Zitat Leemans CR, Tiwari R, Nauta JJ et al (1993) Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer 71:452–456PubMedCrossRef Leemans CR, Tiwari R, Nauta JJ et al (1993) Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer 71:452–456PubMedCrossRef
9.
Zurück zum Zitat Leibel SA, Scott CB, Mohiuddin M et al (1991) The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: results of an analysis from the RTOG head and neck database. Int J Radiat Oncol Biol Phys 21:549–556PubMedCrossRef Leibel SA, Scott CB, Mohiuddin M et al (1991) The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: results of an analysis from the RTOG head and neck database. Int J Radiat Oncol Biol Phys 21:549–556PubMedCrossRef
10.
Zurück zum Zitat Marur S, D’Souza, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11:781–789PubMedCrossRef Marur S, D’Souza, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11:781–789PubMedCrossRef
11.
Zurück zum Zitat Nguyen NP, Vock J, Chi A et al (2012) Impact of intensity-modulated and image-guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer. Strahlenther Onkol 188:677–685PubMedCrossRef Nguyen NP, Vock J, Chi A et al (2012) Impact of intensity-modulated and image-guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer. Strahlenther Onkol 188:677–685PubMedCrossRef
12.
Zurück zum Zitat Petersen I, Schewe C, Schlüns K et al (2007) Inter-laboratory validation of PCR-based HPV detection in pathology specimens. Virchows Arch 451:701–716PubMedCrossRef Petersen I, Schewe C, Schlüns K et al (2007) Inter-laboratory validation of PCR-based HPV detection in pathology specimens. Virchows Arch 451:701–716PubMedCrossRef
13.
Zurück zum Zitat Rades D, Seibold ND, Gebhard MP et al (2011) Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). Strahlenther Onkol 187:626–632PubMedCrossRef Rades D, Seibold ND, Gebhard MP et al (2011) Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). Strahlenther Onkol 187:626–632PubMedCrossRef
14.
Zurück zum Zitat Rades D, Stoehr M, Kazic N et al (2008) Locally advanced stage IV squamous cell carcinoma of the head and neck: impact of pre-radiotherapy hemoglobin level and interruptions during radiotherapy. Int J Radiat Oncol Biol Phys 70:1108–1114PubMedCrossRef Rades D, Stoehr M, Kazic N et al (2008) Locally advanced stage IV squamous cell carcinoma of the head and neck: impact of pre-radiotherapy hemoglobin level and interruptions during radiotherapy. Int J Radiat Oncol Biol Phys 70:1108–1114PubMedCrossRef
15.
Zurück zum Zitat Wentzensen N, Knebel-Doeberitz M (2004) Viral cancerogenesis of head and neck tumors. Pathologe 25:21–30PubMedCrossRef Wentzensen N, Knebel-Doeberitz M (2004) Viral cancerogenesis of head and neck tumors. Pathologe 25:21–30PubMedCrossRef
Metadaten
Titel
Impact of the HPV-positivity definition on the prognostic value of HPV status in patients with locally advanced squamous cell carcinoma of the head and neck
verfasst von
D. Rades, M.D.
N.D. Seibold
M.P. Gebhard
F. Noack, M.D.
C. Thorns, M.D.
S.E. Schild, M.D.
Publikationsdatum
01.10.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 10/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-013-0377-3

Weitere Artikel der Ausgabe 10/2013

Strahlentherapie und Onkologie 10/2013 Zur Ausgabe

Mitteilungen der Fachgesellschaften

Mitteilungen der Fachgesellschaften

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.